|
|
|
| Effect of Sulodexide on diabetic nephropathy |
| GAO Junjie WANG Weisong WANG Fangli SU Zhiguo |
| No.1 Department of Nephrology, Cangzhou Central Hospital, Hebei Province, Cangzhou 061000, China |
|
|
|
Abstract Objective To investigate the clinical effect of Sulodexide in the treatment for diabetic nephropathy (DN) patients. Methods A total of 200 patients with DN from January 2011 to January 2018 in Cangzhou Central Hospital, Hebei Province were enrolled in this study. They were divided into combined group and control group by random number table method, with 100 patients in each group. The control group was given basal therapy as hypoglycemic and microcirculation treatment. The combined group was treated with Sulodexide on the basis of the treatment in the control group. The fasting blood-glucose (FPG), blood glucose 2 h after meal (2 h PG), 24 h urinary albumin excretion rate (24 h UAER), serum creatinine (Scr), serum malonaldehyde (MDA), superoxide dismutase (SOD), the number of urinary podocytes, blood and urine monocyte chemoattractant protein 1(MCP-1) were compared before and after treatment. Results After treatment, 24 h UAER, Scr, MDA and urinary podocytes in both groups were significantly lower than those before treatment (P ＜ 0.05), the SOD of the two groups were significantly higher than those before treatment (P ＜ 0.05). After treatment, 24 h UAER, Scr, MDA and urinary podocytes in the combined group were lower than those in the control group (P ＜ 0.05), and SOD was higher than that of the control group (P ＜ 0.05). After treatment, blood and urine MCP-1 of the two groups were significantly lower than those before treatment (P ＜ 0.05), and the blood and urine MCP-1 in the combined group were lower than those in the control group (P ＜ 0.05). Conclusion Sulodexide in the treatment of DN can significantly reduce oxidative stress, blood and urine MCP-1 levels, urinary podocyte levels, and improve renal function.
|
|
|
|
|
|
[1] 冯罡，李军，王晓丽，等.糖尿病肾病患者血清microRNA-21含量及其与氧化应激指标的相关性[J].中国现代医学杂志，2017，27（1）：60-63.
[2] 孙晓兰，陈敏.炎症损伤和氧化应激损伤对糖尿病肾病患者尿微量白蛋白/肌酐、24 h尿微量白蛋白的影响[J].海南医学院学报，2017，23（5）：623-626.
[3] 叶任高，陆再英.内科学[M].6版.北京：人民卫生出版社，2004：797-798.
[4] 中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识（2014年版）[J].中华糖尿病杂志，2014， 6（11）：792-801.
[5] 徐元华，王梅.糖尿病肾病患者接受酮酸联合低蛋白饮食后氧化应激损伤程度、RAS活性、足细胞脱落情况的评估[J].海南医学院学报，2016，22（6）：551-554.
[6] 林秀珠.糖尿病肾病患者抑郁情绪对肾功能以及氧化应激反应、炎症反应的影响[J].海南医学院学报，2017，23（5）：701-704.
[7] 李永刚.舒洛地特联合缬沙坦治疗原发性肾小球肾炎的临床疗效[J].系统医学，2016，1（7）：31-32.
[8] Ohigashi M，Imai N，Toba H，et al. Pitavastatin Exhibits Protective Effects on Podocytes Accompanied by BMP-7 Up-Regulation and Rho Suppression [J]. Pharmacology，2016，97（5/6）：265.
[9] 张洪波，孙婷丽，谢长英，等.肾炎康复片联合舒洛地特治疗早期慢性肾脏病观察[J].中国药师，2016，19（1）：106-108.
[10] 杨薪博，吴洁琼，孙杰.肾炎舒联合氯沙坦对早期DN患者尿足细胞及炎症因子的影响[J].西南国防医药，2017， 27（10）：1068-1071.
[11] Lee HW，Khan SQ，Khaliqdina S，et al. Absence of miR-146a in podocytes increases risk of diabetic glomerulopathy via upregulation of erbb4 and notch-1 [J]. J Biol Chem，2017，292（2）：732.
[12] 狄建宁，吴艳佳.舒洛地特对糖尿病肾病患者肾功能及血脂水平的影响[J].宁夏医科大学学报，2016，38（1）：63-65.
[13] 胡漪玲，关文明，徐伟芹.益肾化湿颗粒联合舒洛地特对早期老年糖尿病肾病氧化应激及内皮功能的影响[J].中国实验方剂学杂志，2016，21（5）：211-214.
[14] 杨涛，陈华茜，张任，等.舒洛地特对2型糖尿病肾病患者血清、尿液ET-1水平的影响[J].实用药物与临床，2017，20（6）：631-634.
[15] 董闪闪，刘璠，郭玉卿，等.硫辛酸对早期糖尿病肾病患者尿足细胞标志蛋白和血浆血管内皮生长因子的影响[J].中国新药与临床杂志，2016，34（7）：487-491.
[16] Guedri Y，Damma KN，Toumi M，et al. Effect of intraperitoneal injection of sulodexide on peritoneal function and albumin leakage in continuous ambulatory peritoneal dialysis patients [J]. Saudi J Kidney Dis Transpl， 2016， 27（6）：1194.
[17] Olde Engberink RH，Vogt L. The renoprotective effects of sulodexide [J]. Drug Des Devel Ther，2016，10（Issue 1）：1233-1234.
[18] Olde ERHG，Heerspink HJL，Dick DZ，et al. Blood pressure-lowering effects of sulodexide depend on albuminuria severity:post hocanalysis of the sulodexide microalbuminuria and macroalbuminuria studies [J]. Br J Clin Pharmacol，2016，82（5）：1351-1357.
[19] 刘曙艳，邓晓明.黄芪联合缬沙坦治疗糖尿病肾病及对尿亮氨酸氨基肽酶、足细胞标志蛋白水平的影响[J].中国现代医学杂志，2016，26（15）：102-105.
[20] 徐光.地奥司明联合舒洛地特治疗下肢深静脉血栓的疗效观察[J].现代药物与临床，2017，32（1）：101-104. |
|
|
|
